Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast CancerBusiness Wire • 10/15/21
2 Large Cap Biotech Leaders Pay Big Dividends and Have Huge Upside Potential24/7 Wall Street • 10/15/21
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021Business Wire • 10/14/21
U.S. FDA Approves Kite's Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaBusiness Wire • 10/01/21
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line SettingBenzinga • 10/01/21
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell LymphomaBusiness Wire • 09/30/21
Gilead Scores Fifth Approval For Trodelvy In Triple-Negative Breast Cancer, This Time In CanadaBenzinga • 09/28/21
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada AuthorizationBusiness Wire • 09/27/21
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19Business Wire • 09/22/21
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021Business Wire • 09/20/21
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT StudyBusiness Wire • 09/16/21